TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kezar Life Sciences ( (KZR) ) has shared an update.
On June 17, 2025, Kezar Life Sciences held its annual stockholders meeting, where key decisions were made regarding the company’s governance and financial oversight. Stockholders elected three nominees to the board of directors, approved executive compensation, and ratified KPMG LLP as the independent auditor for the fiscal year ending December 31, 2025.
The most recent analyst rating on (KZR) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Kezar Life Sciences stock, see the KZR Stock Forecast page.
Spark’s Take on KZR Stock
According to Spark, TipRanks’ AI Analyst, KZR is a Neutral.
Kezar Life Sciences faces significant challenges typical of early-stage biotech companies, with no revenue and ongoing losses. While the balance sheet shows stability, the company is reliant on external funding. Technical indicators suggest negative momentum, and the valuation metrics are unattractive due to negative earnings. The lack of earnings call and corporate events data further impacts the assessment.
To see Spark’s full report on KZR stock, click here.
More about Kezar Life Sciences
Average Trading Volume: 33,767
Technical Sentiment Signal: Sell
Current Market Cap: $33.02M
Find detailed analytics on KZR stock on TipRanks’ Stock Analysis page.